Pharma BD Deal Intelligence
A $1.27B AstraZeneca acquisition of TeneoTwo for its single-asset bispecific TNB-486 is validating in real time: renamed AZD0486 (surovatamig), the CD19xCD3 T-cell engager posted a 96% overall response rate in relapsed follicular lymphoma at ASH 2024 and now anchors a Phase 3 pivotal trial against chemoimmunotherapy.
AstraZeneca acquired TeneoTwo for $1.3B for blood cancer drug portfolio.
SOUNDTRACK-F1 (NCT06549595): Phase 3, surovatamig (AZD0486) + rituximab vs chemoimmunotherapy in previously untreated follicular lymphoma; Recruiting.
AstraZeneca to acquire TeneoTwo in deal worth up to $1.26 billion to strengthen haematological cancer pipeline with bispecific T-cell engager.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
AstraZeneca acquired US biotech TeneoTwo (a TeneoBio spinout) to add its single clinical-stage asset, TNB-486 — a fully human CD19xCD3 bispecific T-cell engager for B-cell hematologic malignancies. The deal was structured as $100M upfront plus up to $805M in R&D milestones and up to $360M in commercial milestones (up to ~$1.27B total). Announced January 2022 and completed August 2022. Since the deal, AstraZeneca renamed the asset AZD0486 (INN surovatamig) and advanced it from Phase 1 to Phase 3: at ASH 2024, doses ≥2.4 mg produced a 96% overall response and 85% complete response with rapid MRD clearance in relapsed/refractory follicular lymphoma, with CRS in 45% of patients but all Grade 1. The pivotal Phase 3 SOUNDTRACK-F1 trial (NCT06549595) now tests surovatamig plus rituximab versus chemoimmunotherapy in previously untreated follicular lymphoma, with Phase 2 SOUNDTRACK-B running in relapsed/refractory NHL — validating the original bispecific T-cell-engager thesis.
81K US cases/yr · $12.0B US NHL Therapeutics Market · ~30% DLBCL Share of NHL
B-cell non-Hodgkin lymphoma encompasses diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and other subtypes. TNB-486 is a bispecific T-cell engager targeting CD19xCD3, designed to redirect T cells to kill CD19-expressing cancer cells. The acquisition strengthened AstraZeneca hematologic oncology pipeline.
CD19-targeting bispecific antibodies represent a rapidly evolving space in hematologic malignancies. Key competitors include Blincyto (blinatumomab, Amgen), Columvi (glofitamab, Roche), and Epkinly (epcoritamab, AbbVie/Genmab). TNB-486 differentiates through its unique antibody architecture designed to improve safety profile vs first-generation bispecifics.
AstraZeneca completed $1.3B acquisition of TeneoTwo, gaining TNB-486 CD19xCD3 bispecific T-cell engager for B-cell lymphomas.
AZ advanced TNB-486 bispecific antibody through clinical development, complementing hematology pipeline with T-cell engaging mechanism.
Surovatamig (AZD0486) advanced to pivotal Phase 3 SOUNDTRACK-F1 (NCT06549595): surovatamig + rituximab vs chemoimmunotherapy in previously untreated follicular lymphoma. Asset moved from Phase 1 at deal to Phase 3.
At doses >=2.4 mg, AZD0486 (CD19xCD3 T-cell engager) produced 96% overall and 85% complete responses with rapid MRD clearance in relapsed/refractory follicular lymphoma; CRS in 45% but all Grade 1.
TNB-486 among several CD19 bispecifics in development. Intense competitive landscape with approved competitors. $1.3B was premium for clinical-stage asset.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / TeneoTwo Inc. (this deal) | 2022 | $1.3B | 54 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2022 deals · AstraZeneca PLC deals · Oncology deals